Want to see SE:INIT full AI Analyst Report?

Initiator Pharma A/S (INIT) Price & Analysis

0 Followers

INIT Stock Chart & Stats

kr2.29

kr0.25(10.92%)

At close: Jul 27 4:00 PM EDT

kr2.29

kr0.25(10.92%)

Day’s Range― - ―

52-Week Rangekr2.11 - kr3.69

Previous CloseN/A

Volume40.71K

Average Volume (3M)113.19K

Market Cap

kr153.33M

Enterprise Valuekr173.87

Total Cash (Recent Filing)kr17.10M

Total Debt (Recent Filing)kr9.69M

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Nov 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding68,452,890

10 Day Avg. Volume72,209

30 Day Avg. Volume113,192

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)4.31

Price to Sales (P/S)0.00

P/FCF Ratio-7.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Clinical StrategyA focused lead program gives the company a clear development strategy and concentrates resources on a defined therapeutic need. Pudafensinil’s intended use in patients who may not respond sufficiently to existing PDE5 inhibitors could support differentiation if clinical development succeeds.

Existing Asset BaseMaintaining 20.9m of total assets provides an existing resource base for continuing development activities and operating the business. This does not remove funding pressure, but it indicates the company retains tangible balance-sheet resources while advancing its clinical-stage pipeline.

Reported FCF GrowthPositive reported free-cash-flow growth offers a limited constructive trend within the latest period, suggesting the rate of deterioration may have improved relative to the prior comparison. However, the company still consumes substantial cash, so this remains only a modest fundamental support.

Bears Say

No Commercial RevenueA continuing absence of revenue confirms that Initiator Pharma remains pre-commercial and dependent on successful development before generating operating sales. Without a revenue base, the company cannot yet demonstrate product-market traction, recurring income, or operating leverage to offset its research costs.

Widening Losses And Cash BurnLosses have widened materially while operating and free cash flow remain deeply negative, showing that the business is consuming cash rather than funding operations internally. Persistent cash-backed losses increase dependence on external financing and could constrain the pace of future development.

Deteriorating Balance SheetHigher debt combined with sharply reduced equity weakens financial flexibility and increases leverage for a company that is still loss-making. The resulting funding profile raises refinancing and dilution risk, potentially limiting management’s ability to finance clinical programs on favorable terms.

INIT FAQ

What was Initiator Pharma A/S’s price range in the past 12 months?

Initiator Pharma A/S lowest stock price was kr2.11 and its highest was kr3.69 in the past 12 months.

What is Initiator Pharma A/S’s market cap?

Initiator Pharma A/S’s market cap is kr153.33M.

When is Initiator Pharma A/S’s upcoming earnings report date?

Initiator Pharma A/S’s upcoming earnings report date is Nov 20, 2026 which is in 63 days.

How were Initiator Pharma A/S’s earnings last quarter?

Initiator Pharma A/S released its earnings results on Aug 21, 2026. The company reported -kr0.202 earnings per share for the quarter.

Is Initiator Pharma A/S overvalued?

According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Initiator Pharma A/S pay dividends?

Initiator Pharma A/S does not currently pay dividends.

What is Initiator Pharma A/S’s EPS estimate?

Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Initiator Pharma A/S have?

Initiator Pharma A/S has 68,452,890 shares outstanding.

What happened to Initiator Pharma A/S’s price movement after its last earnings report?

Initiator Pharma A/S reported an EPS of -kr0.202 in its last earnings report. Following the earnings report the stock price went up 2.372%.

Which hedge fund is a major shareholder of Initiator Pharma A/S?

Currently, no hedge funds are holding shares in SE:INIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Initiator Pharma A/S

Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.